Pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid tumor progression, high metastatic potential and profound chemoresistance. We recently reported that induction of a chemoresistant phenotype in the PDAC cell line PT45-P1 by long-term chemotherapy involves an increased interleukin 1 beta (IL1b)-dependent secretion of nitric oxide (NO) accounting for efficient caspase inhibition. In the present study, we elucidated the involvement of L1CAM, an adhesion molecule previously found in other malignancies, in this NO-dependent chemoresistance. Chemoresistant PT45-P1res cells, but not chemosensitive parental PT45-P1 cells, express high levels of L1CAM in an ILb-dependent fashion. PT45-P1res cells subjected to short interfering RNA (siRNA)-mediated L1CAM knock-down exhibited reduced inducible nitric oxide synthase expression and NO secretion, as well as a significant increase of anticancer drug-induced caspase activation, an effect reversed by the NO donor S-nitroso-N-acetyl-D,L-penicillamine. Conversely, overexpression of L1CAM in PT45-P1 cells conferred anti-apoptotic protection to anti-cancer drug treatment. Interestingly, L1CAM ectodomain shedding, in example, by ADAM10, as reported for other L1CAM-related activities, seemed to be dispensable for antiapoptotic protection by L1CAM. Neither the shedded L1CAM ectodomain was detected in chemoresistant L1CAM-expressing PT45-P1 cells nor did the administration of various metalloproteinase inhibitors affect L1CAM-dependent chemoresistance. Immunohistochemical analysis revealed L1CAM expression in 80% of pancreatic cancer specimens, supporting a potential role of L1CAM in the malignancy of this tumor. These findings substantiate our understanding of the molecular mechanisms leading to chemoresistance in PDAC cells and indicate the importance of L1CAM in this scenario.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is 4-5th in the rank order of fatal tumor diseases in Western countries, with a 5-year survival rate o2% and a still increasing prevalence (Lockhart et al., 2005; Schneider et al., 2005) . Owing to its largely symptomless progression, PDAC is diagnosed in an already advanced stage with wide-spread metastasis, and for 80-90% of the patients, no option for a curative surgical resection exists anymore at the time of diagnosis. For these patients, current therapeutical options rely on chemotherapy treatment with 5-fluoruracil or gemcitabine, but solely with palliative intention. The failure of all chemotherapeutic strategies is largely based on the profound chemoresistance of PDAC cells that either results from pre-existing intrinsic mechanisms or from an extrinsic induction by anti-cancer drug treatment itself. Irrespective of these mechanisms, the capability of PDAC cells to evade the effect of cytostatic drugs mainly results from an efficient protection against drug-induced apoptosis. We have previously shown (Muerkoster et al., 2004) that intense double paracrine interactions of PDAC cells with surrounding stromal fibroblasts led to the induction and manifestation of anti-apoptotic protection in these tumor cells involving an elevated interleukin 1 beta (IL1b)-dependent release of nitric oxide (NO). Both cellular mediators are also induced in PDAC cells after extended cytostatic drug exposure that similarly results in a chemoresistant phenotype (Muerkoster et al., 2006) . Furthermore, the IL1b-dependent NO secretion led to a broad inhibition of caspases, in example, caspase-3, -7, -8 and -9 in longterm drug-treated PT45-P1res cells (Sebens Muerkoster et al., 2006) . As chemoresistant PT45-P1res cells also show altered adhesion properties, we elucidated whether the expression of certain adhesion molecules is functionally related to the gain of chemoresistance in PDAC. Meanwhile, a number of studies show that the chemosensitivity of cancer cells is affected by the extent of cell adhesion and expression of intercellular adhesion molecules (reviewed by St Croix and Kerbel, 1997). Miyamoto et al. (2004) showed that acquired chemoresistance of pancreatic cancer cells depends on the expression of and adhesion to extracellular matrix proteins. Recently, the adhesion molecule L1CAM/ CD171 has attracted much attention as its expression is found in an increasing number of tumors, in example, melanoma, glioma, ovarial and colon cancer, gastrointestinal stromal tumors or neuroendocrine pancreatic carcinoma (Izumoto et al., 1996; Gast et al., 2005; Gavert et al., 2005; Meier et al., 2006; Kaifi et al., 2006a, b) . In several tumors, high L1CAM expression could be associated with poor prognosis and short survival times (Fogel et al., 2003; Kaifi et al., 2006a, b) . L1CAM was initially detected in neuronal cells where it is involved in several biological processes like neuronneuron adhesion, neurite fasciculation, synaptogenesis, neurite outgrowth of Schwann cells and neuronal cell migration (Schachner, 1997; Brummendorf et al., 1998; Hortsch, 2000) .
L1CAM is a 200-220 kDa glycoprotein and a member of the immunoglobulin superfamily. It consists of six immunoglobulin-like domains at the amino-terminal end of the molecule followed by five fibronectin type III homologous repeats, a single transmembrane region and a short intracellular domain (Moos et al., 1988) . Besides its cell-surface localization, L1CAM can also be cleaved by several proteases, in example, the matrix metalloproteinases ADAM10 and ADAM17, or by g-secretases (Maretzky et al., 2005) . Soluble L1CAM has been reported to be important for migration of neuronal as well as of tumor cells (Mechtersheimer et al., 2001; Maretzky et al., 2005) , and several studies support a role for L1CAM in tumor growth , tumor cell invasion and metastasis of melanoma, ovarial and colon cancer (Mechtersheimer et al., 2001; Fogel et al., 2003; Gavert et al., 2005) . Up to now, no data exist on L1CAM expression in PDAC and its role in the protection of drug-induced apoptosis. As Loers et al. (2005) showed that L1CAM-mediated neuroprotection is associated with caspase inhibition, the aim of the present study was to investigate whether L1CAM is expressed in PDAC and whether it is involved in reduced caspase activation and, thereby, in chemoresistance of PDAC cells.
Results

L1CAM expression in chemoresistant PT45-P1res cells is IL1b dependent
Chemoresistant PT45-P1res cells yielded from a 6-week treatment with low-dose etoposide show altered adhesive properties in comparison with the parental chemosensitive cell line PT45-P1 (unpublished observations). We therefore analysed the involvement of adhesion molecules in the chemoresistance of these cells. Interestingly, PT45-P1res cells exhibited a much higher expression of the adhesion molecule L1CAM than PT45-P1 cells, as shown by Western blotting L1CAM is involved in the mediation of chemoresistance in PT45-P1res cells To verify that L1CAM is directly involved in the mediation of chemoresistance, its expression in PT45-P1res cells was blocked by short interfering RNA (siRNA) treatment. Two different L1CAM-specific siRNAs were positively tested for reducing L1CAM expression along with an increase of etoposide-induced caspase-3/-7 activity (Figure 3a ). Owing to its greater sensitizing potential, the L1CAM-specific siRNA-2 was used for further experiments. As shown by L1CAM immunostaining and flow cytometry (Figure 3b ), treatment with this siRNA also reduced L1CAM surface expression. The specificity of L1CAM siRNA was verified by the detection of av integrin expression in PT45-P1res cells, exhibiting unaltered levels after transfection with control or L1CAM siRNA ( Figure 3c ). Moreover, L1CAM knock-down led to a significant apoptosis induction in these cells after treatment with anti-cancer drugs as determined by annexinV staining (Figure 3d , left panel) or by a luminescent caspase-3/-7 activity assay ( Figure 3d , right panel). In comparison with control siRNA transfectants, etoposide-and gemcitabine-induced caspase-3/-7 activity was increased by 48 and 50%, respectively, and annexinV staining was raised by 63 and 67%, respectively. Furthermore, treatment with an anti-L1CAM antibody before exposure to the cytostatic drug similarly abolished chemoresistance of PT45-P1res cells, as analysed by annexinV staining and caspase-3/-7 activity, respectively ( Figure 
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Figure 3 L1CAM is involved in the mediation of chemoresistance in PT45-P1res cells. (a) PT45-P1 res cells were transfected with control siRNA or with two L1CAM-specific siRNAs. Western blotting for the detection of full-length L1CAM or of HSP90 as a control for equal protein load was performed (upper panel). In parallel, siRNA-transfected PT45-P1res cells were treated with 20 mg/ml etoposide or not for 24 h and caspase-3/-7 activity was determined. (b) siRNA-transfected PT45-P1res cells were subjected to L1CAM immunostaining (L1-11A antibody) or staining with an isotype-matched control antibody followed by flow cytometry. One representative histogram is shown. (c) siRNA-transfected PT45-P1res cells were analysed by Western blotting for the detection of full-length L1CAM, av-integrin or HSP90 (d) After overnight siRNA transfection, cells were either left untreated or treated with 20 mg/ml etoposide or 5 mg/ml gemcitabine for 24 h, followed by either AnnexinV/PI staining and flow cytometry (AnnexinVpositive cells over basal) or by caspase-3/-7 assay (n-fold-induced caspase-3/-7 activity of basal). (e) PT45-P1res cells were either left untreated (w/o) or treated with 20 mg/ml etoposide in the absence (w/o) or presence of either 5 mg/ml anti-L1CAM antibody (Clone L1-11A) or 5 mg/ml isotype-matched control antibody. After 24 h, cells were analysed by AnnexinV/PI staining or by caspase-3/-7 assay. Means7s.d. from three independent experiments are shown. *Po0.05.
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Similar findings were obtained with two other chemoresistant PDAC cell lines. In Colo357 and Panc1 cells that exhibited high L1CAM expression, the siRNA-mediated knock-down of L1CAM ( Figure 4a ) led to sensitization towards treatment with etoposide (Figure 4b) , as shown by an increased (64 and 85%, respectively) caspase-3/-7 activity.
In accordance with these data, overexpression of L1CAM (Figure 5a and b) significantly reduced the sensitivity of PT45-P1 cells towards cytostatic druginduced apoptosis in comparison with mock-transfected cells (Figure 5c ). In response to treatment with etoposide and gemcitabine, annexinV staining was decreased by 34 and 30%, respectively, and caspase-3/-7 activity was reduced by 32 and 38%, respectively. These findings support the role of L1CAM in the gain and manifestation of chemoresistance.
L1CAM cleavage is dispensable for induction of chemoresistance in PT45-P1res cells As several biological functions of L1CAM depend on its ectodomain cleavage by certain proteinases, yielding soluble L1CAM, we investigated whether L1CAM cleavage is essential for chemoresistance induction. For this purpose, PT45-P1res cells were either left untreated or were treated with the matrix metalloproteinase inhibitors Tapi-0, Tapi-1 or GM6001, or with the g-secretase inhibitor L685,458. After 24 h, cellular lysates were analysed for L1CAM cleavage by using either the monoclonal antibody UJ127 from Acris, detecting the extracellular part of the protein, or the pcytL1 antibody recognizing the cytoplasmic part of the full-length form of L1CAM and of the C-terminal fragment emerging from proteinase cleavage. Incubation of PT45-P1res cells with either of the inhibitors did not change L1CAM expression, as indicated by the constant amount of the full-length form (220 kDa) of L1CAM as well as of its cytoplasmic 32 kDa fragment (Figure 6a ). Furthermore, these inhibitors did not significantly affect apoptosis induction after etoposide treatment, as determined by caspase-3/-7 assay (Figure 6b ). In line with these findings, incubation of L1CAM-transfected PT45-P1 cells with the matrix metalloproteinase inhibitors or L685,458 did neither influence the expression of full-length L1CAM nor increase the level of the 32 kDa fragment (Figure 6c Figure 6d ). These data indicate that L1CAM cleavage is dispensable for mediation of chemoresistance.
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L1CAM mediates iNOS induction and NO release in PT45-P1res cells
In order to prove whether L1CAM-mediated chemoresistance is linked to enhanced NO release and subsequent caspase inhibition in PT45-P1res cells, as we have recently demonstrated (Sebens Muerkoster et al., 2006) , iNOS mRNA expression and NO release were analysed in PT45-P1res cells subjected to L1CAM knock-down. As shown in Figure 7a , transfection of PT45-P1res cells with L1CAM siRNA clearly reduced the amount of iNOS mRNA. Accordingly, NO levels were significantly diminished in cell culture supernatants of PT45-P1res cells after L1CAM knock-down compared to controltransfected PT45-P1res cells (from 4.9 to 0.9 mmol/10 5 cells; Figure 7b ). Furthermore, NO levels could be decreased in control siRNA-transfected PT45-P1res cells by IL1-RA treatment, whereas in those cells with already diminished NO formation during L1CAM knock-down no further reducing effect of the IL1-RA on NO levels was observed (Figure 7b ). Accordingly, etoposide-induced caspase activation was increased in control-transfected PT45-P1res cells by IL1-RA treatment but not in L1CAM siRNA-transfected cells (Figure 7c ). These data underscore the involvement of L1CAM in the IL1b-dependent NO secretion and chemoresistance induction in PT45-P1res cells.
Chemoresistance of PT45-P1res cells depends on L1CAM-mediated NO secretion Next, it was further analysed whether the induction of chemoresistance by L1CAM depends on L1CAM-mediated NO secretion. For this purpose, L1CAM expression was suppressed by siRNA transfection in PT45-P1res cells subjected to treatment with etoposide in the absence or presence of the NO donor S-nitroso-Nacetyl-D,L-penicillamine (SNAP). As shown by caspase-3/-7 assay, SNAP treatment restored the chemoresistant phenotype in PT45-P1res cells after L1CAM knockdown (Figure 8 ). Whereas L1CAM siRNA-transfected cells showed a 2.3-fold induction in caspase-3/-7 activity after etoposide treatment compared to 1.6-fold induction in control-siRNA transfectants, additional SNAP treatment completely reversed the increased caspase Figure 9 ). In peritumoral areas, nerves and germinal centers of lymph nodes were intensely stained, whereas normal epithelial cells exhibited no L1CAM expression at all. Interestingly, the strongest L1CAM expression could be detected in grade 3 tumors (Table 1 ). These data imply that L1CAM is an important mediator in the malignant transformation and thereby in chemoresistance of pancreatic adenocarinoma.
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Discussion
The present study shows, for the first time, that the adhesion molecule L1CAM plays an important role in (b) siRNA-transfected cells (16 h) were either left untreated or were treated with 250 ng/ml IL1-RA for 24 h. Then, supernatants were cleared and subjected to a commercial NO assay. The amount of NO was normalized to equal cell number, which was determined in parallel (expressed as mmol NO/10 5 cells). (c) siRNA-transfected cells (16 h) were either left untreated or were treated with 250 ng/ml IL1-RA and 20 mg/ml etoposide, either alone or in combination, for 24 h. Then, cells were analysed for caspase-3/-7 activity expressed as n-fold-induced caspase-3/-7 activity of basal. Means7s.d. from three independent experiments are shown. *Po0.05. Muerkoster et al., 2006) . As shown by the present data, the adhesion molecule L1CAM is involved in IL1b-mediated NO release and the resulting caspase inhibition, thus providing an interesting link between cell adhesion and apoptosis protection. Whereas chemosensitive PT45-P1 cells express only little L1CAM, longterm drug treatment increased expression levels of L1CAM in chemoresistant PT45-P1res cells. Interestingly, increased L1CAM expression has been similarly seen in chemoresistant Colo357 and Panc1 cells, as well as in PT45-P1 and T3M4 cells derived from continuous coculture with pancreatic stromal fibroblasts, thereby gaining a chemoresistant phenotype (unpublished observations). Drug-induced L1CAM expression seems to be dependent on IL1b, as treatment with the IL1-RA diminished L1CAM levels in PT45-P1res cells and knock-down experiments with specific L1CAM siRNA underlined the importance of L1CAM in the induction of chemoresistance in these cells. This close relation between the expression of L1CAM and IL1b is also indicated by the fact that particularly grade-2 and grade-3 tumors exhibit most intensive immunostaining not only for L1CAM (Table 1) but also for IL1b, as shown recently (Mu¨erko¨ster et al., 2004) . Moreover, L1CAM transfection of PT45-P1 cells significantly decreased chemosensitivity towards cytostatic drug treatment, supporting the role for L1CAM in protection from drug-induced apoptosis. Loers et al. (2005) could demonstrate that neuritogenesis and neuroprotection from oxidative stress and staurosporine treatment are both dependent on L1CAM expression. Interestingly, proteolytic cleavage of L1CAM, which is a prerequisite for neuroprotection and also for mediation of cell migration and invasion (Mechtersheimer et al., 2001; Gast et al., 2005) , is obviously not essential for mediation of chemoresistance. Neither the broadspectrum matrix metalloproteinase inhibitors Tapi-0, Tapi-1 and GM6001, respectively, nor the g-secretase inhibitor L685,458 affected the expression of the fulllength membrane-bound form of L1CAM. Additionally, the faint expression of the cytoplasmic 32 kDa L1CAM fragment, which is originated after cleavage, did not differ between PT45-P1res and PT45-P1 cells and did not change upon treatment with these inhibitors. Furthermore, none of the soluble fragments could be detected in supernatants of these differently treated PT45-P1res cells (data not shown).
L1CAM-triggered neuroprotection has been shown to be associated with increased phosphorylation of ERK1/ 2, Akt und Bad, as well as inhibition of caspase-9 (Loers et al., 2005) . In contrast, PT45-P1res cells that exhibit increased L1CAM expression and an impaired activity of the initiator caspase-8 and -9 as well as the effector caspase-3 and -7, accounting for anti-apoptotic protection against cytostatic drugs, do not show significant changes in Akt and ERK1/2 phosphorylation (data not shown).
As we recently demonstrated, this broad caspase inhibition in PT45-P1res cells is apparently caused by nitrosylation of cysteine residues in the active site of these enzymes (Sebens Muerkoster et al., 2006) . Nitrosylation is mediated by IL1b-induced NO levels in chemoresistant PDAC cells, a process obviously dependent on L1CAM. Inhibition of L1CAM expression significantly reduced iNOS induction and NO release in PT45-P1res cells thereby enhancing caspase activation and apoptosis induction. Furthermore, L1CAM knock-down clearly impaired induction of iNOS mRNA level and NO secretion by IL1b. Castellani et al. (2002) demonstrated that interaction of L1CAM with neuropilin-1, a receptor for semaphorins and a coreceptor for VEGF, leads to enhanced NO synthesis. NO synthesis can be induced by interaction of L1CAM and neuropilin-1 on one cell (cis) or by interaction of both molecules on different cells (trans). Moreover, it has been shown that PDAC cells highly express neuropilin-1 (Fukahi et al., 2004) and that overexpression of neuropilin-1 is able to induce chemoresistance in PDAC cells (Wey et al., 2005) . As both PT45-P1res and PT45-P1 cells exhibit neuropilin-1 expression (unpublished observation), it seems likely that cis and trans interactions of neuropilin-1 with L1CAM increase iNOS expression and NO synthesis, thereby leading to chemoresistance in PT45-P1res cells. The fact that immunohistochemical analysis of PDAC sections revealed strong L1CAM expression in 80% of the tumor samples and that chemoresistent PDAC cells derived from coculture with stromal fibroblasts also exhibit increased L1CAM expression underscore the role of L1CAM in the induction of chemoresistance in this tumor entity. 
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Besides its role in the gain of chemoresistance, L1CAM might also be of importance for invasion and metastasis of PDAC cells, a role that has to be defined yet. Taking all these findings into account, L1CAM represents an interesting therapeutic target to overcome chemoresistance and to concomitantly interfere with the process of metastasis.
Materials and methods
Cell lines and culture
The human PDAC cell line PT45-P1 as well as its handling was described previously (Kalthoff et al., 1993) . PT45-P1 and PT45-P1res cells were kept in culture (371C, 5% CO 2 , 85% humidity) using RPMI 1640 medium (PAA Laboratories, Co¨lbe, Germany) supplemented with 1% glutamine (Life Technologies, Eggenstein, Germany) and 10% fetal calf serum (FCS) (Biochrom KG, Berlin, Germany). The generation of PT45-P1res cells was performed as described elsewhere (Sebens Muerkoster et al., 2006) . The human PDAC cell lines Colo357 and Panc1 were kindly provided by H Kalthoff (UKSHCampus Kiel) and kept in culture using RPMI 1640 medium supplemented with 1% glutamine, 10% FCS and 1% sodium pyrovate (Biochrom).
Antibodies and reagents
Recombinant human IL-1b and the IL1-RA were obtained from R&D Systems (Wiesbaden, Germany). The matrix metalloproteinase inhibitors GM6001, Tapi-0 and Tapi-1 were obtained from Calbiochem (via Merck Biosciences, Schwalbach/Ts, Germany) and the g-secretase inhibitor L685,458 was purchased from Sigma-Aldrich Chemie (Taufkirchen, Germany). SNAP was purchased from Alexis (Gru¨nberg, Germany). Etoposide was purchased from Bristol Myers Squibb (Mu¨nchen, Germany) and gemcitabine from Lilly (Bad Homburg, Germany). The following antibodies were used for the detection of L1CAM by Western blotting: mouse monoclonal anti-L1CAM detecting the full-length 220 kDa molecule, soluble 85 and 200 kDa fragments (clone UJ127 from Acris Antibodies, Hiddenhausen, Germany) and a rabbit polyclonal anti-pcytL1 antibody detecting the cytoplasmic part of L1CAM (220, 85 and 32 kDa fragments) as described previously (Mechtersheimer et al., 2001) . For blocking experiments and flow cytometry analysis, the monoclonal mouse L1-11A antibody anti-L1CAM (subclone of UJ127.11) was used (Mechtersheimer et al., 2001) . Maus IgG control antibody was obtained from Chemicon (Hampshire, United Kingdom).
AnnexinV/PI staining and caspase-3/-7 assay As described elsewhere (Sebens Muerkoster et al., 2006) , apoptosis was determined by staining with annexinV/propidium iodide (Biocarta, Hamburg, Germany) and subsequent fluorescence flow cytometry (GalaxyArgon Plus; DAKO Cytomation, Hamburg, Germany) using the FLOMAX software, and by detection of caspase-3/-7 activity using a homogeneous luminescent assay (Promega, Mannheim, Germany). All samples were measured in duplicate.
Cell transfection
For L1CAM transfection, PT45-P1 cells were seeded into sixwell plates (2 Â 10 5 cells/well), were grown overnight, followed by transfection with 5 ml/well DIMRIE reagent (Invitrogen, Karlsruhe, Germany) and 0.6 mg/well the following plasmids: pcDNA3.1 (mock) or pcDNA3.1-L1CAM (L1CAM). Upon transfection for 18 h, 1 ml medium containing 20% FCS was added and cells were left untreated or were treated, as indicated, for further 24 h. For knock-down of L1CAM, PT45-P1res cells were seeded into 12-well plates (1 Â 10 5 cells/ well), were grown overnight followed by transfection with 12 ml/well RNAiFect reagent (Invitrogen) and 2 mg/well either Stealth negative control siRNA (Invitrogen) or Stealth L1CAM siRNA (Invitrogen). After overnight transfection, cells were either left untreated or treated as indicated for further 24 h.
L1CAM surface staining and flow cytometry After washing in phosphate-buffered saline (PBS), cells grown in six-well culture plates were detached with 5 mmol/l ethylenediaminetetraacetic acid (EDTA) in PBS and then washed with PBS once again. Blocking was conducted in 1% bovine serum albumin (BSA)/PBS for 60 min at room temperature followed by incubation with the anti-L1CAM antibody L1-11A or an isotype-matched control antibody (1: 1000, in 1% BSA/PBS) at 41C overnight. Then, cells were washed three times in PBS followed by incubation (60 min, 371C) with a goat anti-mouse antibody conjugated with Alexa flour 488 (Dianova, Hamburg, Germany) diluted 1:500 in 1% BSA/PBS. After washing in PBS, cells were resuspended in 500 ml PBS and analysed by fluorescence flow cytometry.
NO assay
Cells were seeded for transfection and cultured as described above. At 48 h after transfection, supernations were taken and precleared by centrifugation (5000 r.p.m., 10 min) before analysis. NO secreted into cell culture supernatants was quantified using the total NO colorimetric assay (R&D Systems). The assay was performed following the manufacturer's instructions. Concentrations of measured NO were normalized to the cell numbers determined in parallel.
Western blotting
Cells were seeded into 6-and 12-well plates and transfected or treated as indicated. Then, cells were washed once with PBS and lysed with 1 volume of 2 Â sodium dodecyl sulfate (SDS) sample buffer (128 mmol/l Tris-Base, 4.6% SDS, 10% glycerol). Samples were heated for 5 min at 951C and put on ice for 2 min. Protein concentrations were determined using the D c Protein assay (BioRad). A 10 mg portion of protein adjusted to an appropriate volume of SDS sample buffer containing 0.2 mg/ml bromophenol blue (Serva, Heidelberg, Germany) and 2.5% b-mercaptoethanol (Biomol, Hamburg, Germany) was submitted to electrophoresis on a 4-20% ProGel-Trisglycin gel (Anamed, Darmstadt, Germany) and immunoblotting was performed as described previously (Arlt et al., 2001) . For detection of L1CAM, a monoclonal antibody (clone UJ127 from Acris Antibodies) was diluted at a concentration of 0.4 mg/ml in 5% nonfat milk powder and 0.05% Tween in Tris-buffered saline (TBS) (blotto) and incubated overnight at 41C. For detection of the cytoplasmic domain of L1CAM, the pcytL1 antibody (Mechtersheimer et al., 2001 ) was used at a concentration of 1 mg/ml in blotto and incubated overnight at 41C. As control of equal protein load, a polyclonal rabbit antibody for HSP90 (Santa Cruz, Heidelberg, Germany) was diluted 1:2000 in blotto. The mouse anti-CD51 antibody from Beckman Coulter GmbH (Krefeld, Germany) was used at a concentration of 1:500 in blotto for detection of human av integrin. Incubation with the primary antibodies was performed overnight at 41C. For detection of the primary antibodies, anti-mouse and anti-rabbit horseradish L1CAM-induced chemoresistance in PDAC cells S Sebens Müerköster et al peroxidase-linked antibodies (Cell Signaling, via New England Biolabs, Frankfurt a.M., Germany) were used at a dilution of 1:2000 in blotto-TBST at room temperature for 1 h. After washing in TBST, blots were developed using the LumiGlo peroxidase detection kit (Cell Signaling).
Real-time PCR
A 2 mg protion of total RNA was reverse-transcribed into single-stranded cDNA, as described previously (Scha¨fer et al., 1999) . A 2 ml protion of cDNA and 0.2 mmol/l gene-specific primers were adjusted with RNAse-free water to a volume of 15 ml. To this mixture, 15 ml of iQ SYBR Green Supermix (BioRad, Munich, Germany) was added. Primers for the detection of L1CAM (Gavert et al., 2005) were used under the following conditions: 951C/1 min; 951C/1 min, 521C/30 s, 721C/ 30 s for 40 cycles; 721C/10 min. Primers for the detection of iNOS were from Biosource (Ratingen, Germany) and used under the following PCR conditions: 951C/5 min; 951C/45 s, 601C/45 s, 721C/45 s for 40 cycles; 721C/10 min. For control, b-actin was amplified in parallel using primers from BD Biosciences Clontech. The real-time PCR was performed with a MyiQ Single Color Real-time PCR Detection System (BioRad). Data were collected during annealing steps and were further analysed by using the i-Cycler iQ Optical system software (BioRad). All samples were analysed in duplicate and data are expressed as the amount of mRNA in arbitrary units.
Immunohistochemistry
Twenty ductal PDAC tissues obtained from surgical specimens according to a protocol approved by the Ethics Committee of the University Hospitals, Kiel (permission number 110/99), were investigated. Routinely processed formalin-fixed sections of human ductal adenocarcinomas were blocked with 0.03% H 2 O 2, followed by heat-mediated antigen retrieval using TRIS-EDTA-citrate buffer in a pressure cooker for 3 min. As a primary antibody, 10 mg/ml of mouse monoclonal anti-L1CAM antibody (Acris Antibodies) was used. The reaction was detected by avidin-biotin-peroxidase using the Vectastain-ABC Kit (Vector Laboratories, Burlingame, CA, USA). For a negative control, the primary antibody was omitted. The immunohistochemical reactions were semiquantitatively scored as mild (o10% of the tumor cells stained), moderate (10-50%) and strong (>50%).
Statistics
Data are presented as mean7s.d. and analysed by Student's t-test. A P-value o0.05 (indicated as * in the figures) was considered as statistically significant.
Abbreviations
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